Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cotoretigene toliparvovec is an investigational, adeno-associated virus serotype 8 (AAV8) vector-based gene therapy designed for subretinal administration. It delivers a full-length, codon optimized retinitis pigmentosa GTPase regulator (RPGR) gene to retinal cells in patients with X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. By replacing the defective or missing RPGR gene, this therapy aims to increase levels of functional RPGR protein and potentially slow, halt, or prevent further degeneration of photoreceptors in affected individuals. Cotoretigene toliparvovec was developed primarily for XLRP and has orphan drug designation for this indication[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cotoretigene toliparvovec.